Nathan S. Bryan, Ph.D.
Founder and CEO
Dr. Bryan earned his undergraduate Bachelor of Science degree in Biochemistry from the University of Texas at Austin and his doctoral degree from Louisiana State University School of Medicine in Shreveport where he was the recipient of the Dean’s Award for Excellence in Research. He pursued his post-doctoral training as a Kirschstein Fellow at Boston University School of Medicine in the Whitaker Cardiovascular Institute. After a two-year post-doctoral fellowship, in 2006 Dr. Bryan was recruited to join faculty at the University of Texas Health Science Center at Houston by Ferid Murad, M.D., Ph.D., 1998 Nobel Laureate in Medicine or Physiology. Dr. Bryan has made many seminal discoveries in the nitric oxide field that has resulted in over a dozen issued US and International patents. He is also a successful entrepreneur who has successfully commercialized his nitric oxide technology. Dr. Bryan led the product development at HumanN and served as Founder and Chief Scientific Officer. Most recently, Dr. Bryan is serving as CEO of Pneuma Nitric Oxide, LLC, a topical skincare and beauty company dedicated to bringing nitric oxide product technologies to the cosmetic arena. His product technology is responsible for hundreds of millions of dollars in revenue generated worldwide. Dr. Bryan has published a number of highly cited papers and authored or edited 5 books. He is an international leader in molecular medicine and nitric oxide biochemistry.
Mr. Huff has over 25 years of experience developing strategic business solutions that exponentially improve top and bottom-line revenue. Mr. Huff is President of GBV Medical Solutions, a Contract Sales Organization (CSO) that offers clients strategic business and sales expertise and delivers more sales, faster and with industry-leading margins. He has developed an independent network of +100 senior executive sales representatives across the United States and Western Europe. Using a consultative approach, Mr. Huff is a strategic, senior-level top producing sales executive with a proven ability to generate $25M+ revenue deals in industry verticals; ICT, healthcare (laboratory, pain management & wound care), retail, and manufacturing). Mr. Huff is a serial entrepreneur with experience and strategic sales skills to engage colleagues and customers at all levels and understand and eliminate sales barriers and ultimately win business, often against much larger competitors. He has maintained meaningful business and personal relationships with CEOs, CIOs, CFOs, Directors, and VPs within the Fortune 500. Mr. Huff has a holistic business perspective. Experienced in managing and leading national and regional sales teams, solution design, product development, finance, operations, marketing, and HR. Full understanding of the cost and impact of these functions and the necessary “team approach” it takes to sell/support a technology product or service. Mr. Huff received his BBA, Business from the University of Mississippi. In the beginning, the company will hire a part-time accountant until such time as a national firm is required. When the time is right the company has a CFO candidate in mind with national and international experience working with a leading medical products manufacturer.
Chief Operating Officer
Chief Operations Officer. Susan Shaffer is forging a fresh path forward for NOi LLC. A long-term colleague and former partner of Dr. Nathan Bryan Ph. D. in a company dedicated to the use of Nitric Oxide in dietary supplementation, Susan is responsible for managing the logistics and operations of NOi. She brings over 30-years of sales, marketing and operations experience delivering effective strategic, relationship, and management skills to such high-profile companies as Lancome, Dell, 3COMM, and HumanN. Currently, Susan Shaffer is serving as President of Pneuma Nitric Oxide, LLC, a topical skincare and beauty company dedicated to bringing nitric oxide in new product innovations within the health and wellness industry. Susan Shaffer is committed to the development and advancement of Nitric Oxide based drug and therapeutic products worldwide.
Robert Arnot, M.D.
Chief Medical Officer
Best selling Author and award-winning war correspondent. Now focusing on Machine Learning with a broad background in systems architecture and user interface. Experience with Google, Apple, NBC News, MSNBC. The second focus is food technology with a deep background in analytical chemistry and human trials. Strong media and communication skills with a Doctor of Medicine (MD). Dr. Bob, Arnot M.D. internal medicine, was born in Boston, Massachusetts, USA as Robert Burns Arnot. He is an award-winning journalist and the chief medical and foreign correspondent for NBC and CBS. He is known for hosting Dr. Danger (TV Series). He also authored 12 books on health and nutrition. He is also the founder and former or current board member of several humanitarian aid organizations. He covered major humanitarian disasters and wards including the Rwandan Genocide, Gulf War I and II, Sudan, and Somalia. His most recent TV appearance is as an infectious disease expert on MetroFocus explaining the side effects of contracting the mosquito-borne Zika virus.
Mr. Perry is the longest-serving Governor in the history of the State of Texas. During his tenure, he was responsible for record economic growth and job creation in the State of Texas. Most recently, Mr. Perry served as Secretary of Energy for the Trump Administration. He has a history of working with the FDA and other regulatory bodies to move innovations forward.
John Somberg, M.D.,
Clinical Trial Principal Investigator/consultant
Dr. Somberg trained as a research cardiologist, cellular, and clinical electrophysiologist. He has worked in a number of pharmacology laboratories (Levitt (NY Medical College), Sonnenblick (Albert Einstein College of Medicine), Tom Smith (Harvard Medical School) in his early career. He then in 1979 established the Clinical Cardiac Arrhythmia Service at Albert Einstein in New York City. Dr. Somberg was a career clinical investigator, serving as a PI in over 100 phase II and phase III pharmaceutical studies, most dealing with anti-arrhythmic agents and has served as an advisor to the Cardio-Renal Division of FDA and on FDA advisory panels (Circulatory Device Panel). These activities eventually resulted in Dr. Somberg’s founding of Academic Pharmaceuticals that has developed two IV formulations of amiodarone, IV sotalol, and now working on an IV diuretic. His company has obtained two NDA’s and two Orphan Drug Designations. Dr. Somberg’s involvement in drug development and the FDA has led him to teach at Rush University, a course on Drug Development, the U.S. Regulatory Process, as part of the Masters in Clinical Research program supported by a K 30 award and ran the program for 20 years as the Director of the Program. He is trained in cardiology, clinical research, anti-arrhythmic pharmacology and has over 250 peer-reviewed publications as well as directing over 100 clinical studies. He has successfully run Academic Pharmaceuticals since 1993, with the company remaining viable through difficult financial times. Under his direction, API obtained Orphan Drug Designation and approval of IV Sotalol, NDA 22-306. Dr. Somberg also was the Editor of the American Journal of Therapeutics, section editor of Therapeutics for the Journal Cardiology, and as an editorial board member of the American Journal of Cardiology. Dr. Somberg for many years maintained basic pharmaceutical chemistry and ion channel laboratory at Rush University Medical Center where he was a Professor of Medicine, Cardiology & Pharmacology, and Chief of the Division of Clinical Pharmacology. After 21 years at Rush, Dr. Somberg retired and is currently Professor Emeritus at Rush University. He has undertaken and supervised studies on a number of antiarrhythmic agents both in the cellular, preclinical and clinical stages that have been the basis of FDA submissions.
Dr. Somberg’s scientific area of emphasis has been related to studies regarding cardiac repolarization changes. He has many patents in this area and has been working on a new anti-arrhythmic agent, combining the efficacy of sotalol with the short-acting beta-blocker, esmolol. His expertise extends to non-cardiac drugs that affect cardiac repolarization and QT interval and their pro-arrhythmia risk. He has also emphasized the re-formulation of drugs, developing them under the 505(b)2 section of FDA regulations, and has multiple patents in this area. He has served as a consultant to industry regarding issues of drug and device development and the QT effects of cardiac and non-cardiac drugs. In addition, Dr. Somberg has been a member of a number of DSM Boards with particular emphasis on QT safety considerations.
Chief Marketing Officer
Jeffrey Adise leads NOi's global marketing efforts. He has over 30 years of medical and product marketing experience introducing hundreds of new products and services to market for such companies as American Home Products, Blue Chip Medical Products, Block Drug, Crown Medical Products, Everlast Sporting Goods, and many others. He has expertise in the creation, development, implementation, measuring, and monitoring of marketing campaigns across the full gambit of platforms including but not limited to print, online, social media, video, radio, and more, Jeff has served as an expert consultant responsible for implementing and improving sales, marketing and operations for US-based B to B and B to C e-commerce companies.
DLA Piper Full Service Law Firm